Search

Search Constraints

You searched for: Author/Creator Pfarr, Egon

Search Results

1. Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced. Issue 4 (26th January 2021)

3. Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease. Issue 1 (3rd May 2021)

6. Empagliflozin in Black Versus White Patients With Heart Failure: Analysis of EMPEROR-Pooled. Issue 1 (7th November 2022)

7. Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial. Issue 11 (12th March 2019)

8. Kidney Function After Initiation and Discontinuation of Empagliflozin in Patients With Heart Failure With and Without Type 2 Diabetes: Insights From the EMPERIAL Trials. Issue 15 (12th October 2021)

9. Kidney Function After Initiation and Discontinuation of Empagliflozin in Patients With Heart Failure With and Without Type 2 Diabetes: Insights From the EMPERIAL Trials. Issue 15 (16th August 2021)

10. Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA. Issue 3 (15th January 2019)